Login to Your Account

Actelion, Merck Enter Oral Renin Inhibitor Pact Worth Up To $272M

By Cormac Sheridan

Wednesday, December 10, 2003
Swiss biopharmaceutical firm Actelion Ltd. added $10 million to its cash pile, on the strength of an exclusive alliance with Merck & Co. Inc. in the area of oral renin inhibitors. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription